Anxu Biological disclosure of the 2022 semi -annual report achieved revenue of 5.930 billion yuan
Author:Capital state Time:2022.08.30
On August 29th, Anxu Biology (code: 688075.SH) released the 2022 semi -annual performance report.
From January 1, 2022-June 30, 2022, the company realized operating income of 5.93 billion yuan, an increase of 1100.35%year-on-year, and net profit was 2.878 billion yuan, an increase of 1323.67%year-on-year, and the basic earnings per share were 46.92 yuan.
The company's industry is a medical device.
During the company's reporting period, the total assets at the end of the period were 7.456 billion yuan, the operating profit was 3.308 billion yuan, the accounts receivable were 481 million yuan, and the net cash flow generated by operating activities was 3.932 billion yuan.The cash was 6.046 billion yuan.
An Xu Bio, the company's full name Hangzhou Anxu Biotechnology Co., Ltd., was established on July 04, 2008. The current general manager Ling Shisheng. The main business is to focus on the research and development, production and sales of POCT reagents and instruments.
- END -
A -share volume climbing funds Focus on core assets
On the 27th, A shares continued to fluctuate, and the market volume could be enlar...
"Chengdu -made" Wanjia Industrial Enterprise Promoting Consumption Insurance Growth Clouds will be launched on July 7th
The reporter learned from the Chengdu Economic and Information Bureau that in order to implement the Party Central Committee and the State Council's decision -making and deployment of the main body of...